Pharma Pipeline Intelligence MCP Server

> View on ApifyForge | Use on Apify Store

---

Quick Start

Add to your MCP client (Claude Desktop, Cursor, Windsurf):

{
  "mcpServers": {
    "pharma-pipeline-intelligence-mcp": {
      "url": "https://ryanclinton--pharma-pipeline-intelligence-mcp.apify.actor/mcp"
    }
  }
}

---

Drug pipeline competitive intelligence for pharmaceutical companies, biotech investors, and medical affairs teams starts here. This MCP server orchestrates 7 live data sources — ClinicalTrials.gov, FDA, EMA, USPTO, and PubMed — to produce a composite Pipeline Threat Score (0-100) with four specialized sub-models. Connect once to any MCP-compatible AI assistant and ask structured pipeline questions in plain language.

The server runs as a persistent Apify Standby actor exposed over HTTP using the MCP protocol. When you call a tool, it fans out to up to 7 actors in parallel, applies four scoring models to the combined data, and returns structured JSON with scores, signals, and supporting records. No code, no API keys to manage for the underlying databases, and no subscriptions.

⬇️ What data can you access?

| Data Point | Source | Example Value |
|---|---|---|
| 📋 Active trials by phase, enrollment, status | ClinicalTrials.gov | Phase 3, 450 patients, RECRUITING |
| ✅ FDA NDA/BLA/ANDA approvals | openFDA Drug Approvals | Ozempic, NDA #209637, 2017-12-05 |
| 🇪🇺 EMA marketing authorizations | European Medicines Agency | Wegovy, EU/1/21/1580, Authorized |
| ⚠️ Adverse event reports (FAERS) | openFDA Drug Events | 847 reports, 23% serious ratio |
| 🔴 Drug recalls by classification | FDA Enforcement | Class I, cardiac risk, national distribution |
| 🔬 Patent filings and expiry dates | USPTO | US10,123,456, expires 2031-08-14 |
| 📚 Publication trends and citation velocity | PubMed | 34 papers last 2 years, accelerating |
| 🏆 Pipeline Threat Score (0-100) | Composite model | Score 67, HIGH threat level |
| 🎯 First-Mover Advantage Index | Composite model | Score 72, 8.5 years exclusivity |
| 📊 Adverse Event Divergence Score | Composite model | Score 31, ELEVATED divergence |
| 📈 Literature Momentum Score | Composite model | Score 58, accelerating trend |
| 🚦 Composite risk level | All 7 sources | MODERATE / HIGH / CRITICAL |

Why use Pharma Pipeline Intelligence MCP?

Building a competitive pipeline analysis by hand means querying ClinicalTrials.gov, navigating the openFDA API, searching USPTO full-text, pulling EMA product data, and combing PubMed — across different schemas, rate limits, and data models. A thorough analyst might spend two days assembling the picture for a single drug. It still arrives without scoring, signal detection, or a cross-source threat rating.

This MCP server automates the entire process. One tool call to generate_pipeline_threat_report fires 7 actors simultaneously, applies four purpose-built scoring models, and returns a composite risk report in under two minutes.

Platform benefits included with every run:

- Scheduling — run weekly competitive landscape sweeps via Apify Scheduler with no cron infrastructure
- API access — trigger any tool from Python, JavaScript, or any HTTP client using the MCP protocol
- Standby mode — the server stays warm with no cold-start latency; requests are handled in milliseconds
- Spending limits — set per-session budget caps so AI assistants cannot overspend on exploratory queries
- Integrations — connect to Zapier, Make, webhooks, or downstream CRM workflows after each tool call

Features

- 8 specialized MCP tools covering every dimension of drug pipeline intelligence, from clinical trials to patent exclusivity to literature velocity
- 7-actor parallel orchestration — the generate_pipeline_threat_report tool fans out to all 7 data sources simultaneously, cutting total latency versus sequential calls
- Pipeline Threat Score with 4 sub-models — Phase 3 density contributes 8 points per competitor (max 40), trial volume caps at 20, recent FDA approvals at 15, EMA approvals at 10, with recall activity reducing threat by up to 15 points
- First-Mover Advantage Index — patent portfolio scores up to 30 points (5 patents = 30), exclusivity duration adds 2.5 points per year of remaining protection (max 25), trial phase lead scores up to 25 points
- Adverse Event Divergence detection — death reports score 7 points each (max 35), serious event ratio above 30% triggers an elevated signal, hospitalization burden adds up to 20 points with log-normalized volume scoring
- Literature Momentum acceleration detection — compares publication counts from the last 2 years against the prior 2-year period; 20% or greater growth triggers an acceleration signal
- Phase detection across naming conventions — recognizes both Arabic numeral (Phase 1, 2, 3, 4) and Roman numeral (Phase I, II, III, IV) trial phase labels from ClinicalTrials.gov
- Composite scoring formula — Pipeline Threat 30% + Adverse Events 25% + Literature Momentum 25% + First-Mover Inverted 20%, calibrated so a strong first-mover position reduces overall risk
- 4-tier risk classification — LOW (0-25), MODERATE (26-50), HIGH (51-75), CRITICAL (76-100) with plain-English signal explanations for each boundary crossed
- Recall intelligence as negative pressure — competitor drug recalls reduce the Pipeline Threat Score (more failed competitors = less threat), a nuance absent from most competitive tools
- Top 10 adverse reaction extraction — MedDRA reaction terms aggregated by frequency across all FAERS reports, sorted descending
- FDA vs EMA regulatory gap analysis — compare_regulatory_pathways computes the raw approval count difference between FDA and EMA, flagging divergence in regulatory acceptance across markets
- Spending limit enforcement — every tool checks Actor.charge() before executing and returns a structured error if the session budget is exhausted

Use cases for drug pipeline competitive intelligence

Biotech investment thesis validation

Pre-IPO analysts and venture partners tracking clinical-stage companies need to quantify pipeline risk before committing capital. The generate_pipeline_threat_report tool produces a scored assessment of competitive crowding, adverse event signals for the target compound, patent protection duration, and research momentum — all in a single call. Compare scores across candidate investments to rank risk-adjusted opportunity.

Competitive landscape monitoring for business development

BD teams evaluating in-licensing targets or co-development partnerships need to understand how crowded a therapeutic area is before negotiating deal terms. The analyze_competitive_landscape tool returns FDA approvals, EMA authorizations, active trial counts, and a Pipeline Threat Score for any drug class or indication, giving deal teams a data-backed view of competitive density within minutes.

Patent cliff and generic entry strategy

Generic drug manufacturers and biosimilar developers tracking branded drug exclusivity windows need precise patent expiry data. The track_patent_exclusivity tool pulls USPTO filings, extracts expiration dates, calculates remaining years of exclusivity, and returns a First-Mover Advantage score — identifying which drugs are approaching patent cliffs and when generic entry windows open.

Safety signal surveillance for medical affairs

Pharmacovigilance and medical affairs teams monitoring the safety profile of a drug or its competitors need early detection of adverse event pattern shifts. The detect_adverse_event_signals tool analyzes FAERS reports, classifies outcomes as NORMAL / ELEVATED / CONCERNING / CRITICAL, and surfaces the top 10 MedDRA reaction terms — complementing enterprise pharmacovigilance systems with a rapid public-data view.

Research strategy and emerging area identification

R&D strategy teams need to identify therapeutic areas gaining momentum before competitors commit resources. The assess_literature_momentum tool scores publication velocity from PubMed, detects acceleration (20% growth threshold), and identifies the top journals covering a research space — signaling where the field is heading before clinical programs are announced.

Regulatory pathway planning for market access

Global market access teams planning multi-region launches need to understand where regulatory gaps exist between FDA and EMA. The compare_regulatory_pathways tool queries both agencies in parallel and returns approval counts with a regulatory gap metric, helping teams sequence launches and anticipate where additional submissions will be needed.

How to use drug pipeline intelligence tools

1. Connect the MCP server to your AI assistant — Add the server URL to your Claude Desktop, Cursor, or Windsurf config (see connection instructions below). No API key setup is needed for the underlying databases.
2. Ask your AI a natural-language question — For example: "Analyze the competitive landscape for GLP-1 agonists in obesity" or "Generate a pipeline threat report for Vertex Pharmaceuticals and ivacaftor."
3. Review the scored output — The AI presents Pipeline Threat Scores, sub-model breakdowns, and plain-English signals derived from live regulatory and clinical data.
4. Set a spending limit — In Apify Console, configure a maximum spend per session to control costs on exploratory research sessions. The server stops when the limit is reached.

⬇️ MCP tools

| Tool | Price | Description |
|------|-------|-------------|
| search_drug_pipeline | $0.045 | Search ClinicalTrials.gov by drug, condition, sponsor, phase, or status. Returns up to 50 trials. |
| analyze_competitive_landscape | $0.045 | FDA approvals + EMA authorizations + active trial count with Pipeline Threat Score for a therapeutic area. |
| detect_adverse_event_signals | $0.045 | FDA FAERS adverse event analysis: serious events, deaths, hospitalizations, top 10 MedDRA reactions, Divergence Score. |
| track_patent_exclusivity | $0.045 | USPTO patent portfolio: filing counts, expiry dates, years of exclusivity remaining, First-Mover Advantage score. |
| compare_regulatory_pathways | $0.045 | Side-by-side FDA vs EMA approval comparison for a drug class with regulatory gap count. |
| monitor_drug_recalls | $0.045 | FDA enforcement database: recall class (I/II/III), manufacturer, distribution scope, class breakdown summary. |
| assess_literature_momentum | $0.045 | PubMed publication velocity: yearly trend, acceleration detection, top 5 journals, Literature Momentum Score. |
| generate_pipeline_threat_report | $0.045 | Full composite report across all 7 sources. Returns 4 sub-model scores + composite Pipeline Threat Score (0-100). |

Tool input parameters

| Tool | Parameter | Type | Required | Description |
|------|-----------|------|----------|-------------|
| search_drug_pipeline | query | string | Yes | Drug name, condition, or therapeutic area |
| search_drug_pipeline | status | string | No | Trial status: RECRUITING, ACTIVE_NOT_RECRUITING, COMPLETED |
| search_drug_pipeline | phase | string | No | Phase filter: PHASE1, PHASE2, PHASE3, PHASE4 |
| analyze_competitive_landscape | query | string | Yes | Drug class, therapeutic area, or active ingredient |
| detect_adverse_event_signals | query | string | Yes | Drug name or active ingredient |
| detect_adverse_event_signals | limit | number | No | Max FAERS records to analyze (default: 100) |
| track_patent_exclusivity | query | string | Yes | Drug name, compound, mechanism, or assignee |
| compare_regulatory_pathways | query | string | Yes | Drug name, active substance, or therapeutic area |
| monitor_drug_recalls | query | string | Yes | Drug name, manufacturer, or recall reason |
| monitor_drug_recalls | classification | string | No | Recall class: Class I, Class II, Class III |
| assess_literature_momentum | query | string | Yes | Drug name, condition, mechanism, or research topic |
| assess_literature_momentum | maxResults | number | No | Max publications to analyze (default: 50) |
| generate_pipeline_threat_report | company | string | Yes | Pharmaceutical company name |
| generate_pipeline_threat_report | drug | string | Yes | Drug name or active ingredient |
| generate_pipeline_threat_report | indication | string | No | Therapeutic indication or condition (appended to search query) |

⬆️ Output example

{
  "company": "Vertex Pharmaceuticals",
  "drug": "ivacaftor",
  "compositeScore": 38,
  "riskLevel": "MODERATE",
  "pipelineThreat": {
    "score": 24,
    "competitorCount": 11,
    "phaseDistribution": {
      "Phase 2": 4,
      "Phase 3": 2,
      "Phase 1": 3
    },
    "sameIndicationTrials": 9,
    "recentApprovals": 2,
    "recentRecalls": 0,
    "threatLevel": "LOW",
    "signals": [
      "2 recent FDA approvals in class"
    ]
  },
  "firstMoverAdvantage": {
    "score": 76,
    "patentsCovering": 5,
    "earliestPatentExpiry": "2031-08-14",
    "yearsOfExclusivity": 5.4,
    "trialPhaseLead": 4,
    "approvalPathwayClear": true,
    "signals": [
      "5.4 years patent exclusivity remaining",
      "Already has 2 FDA approval(s)"
    ]
  },
  "adverseEventDivergence": {
    "score": 29,
    "totalReports": 214,
    "seriousEvents": 58,
    "deathReports": 1,
    "hospitalizationReports": 12,
    "seriousRatio": 0.271,
    "divergenceLevel": "ELEVATED",
    "topReactions": [
      { "term": "COUGH", "count": 31 },
      { "term": "NAUSEA", "count": 24 },
      { "term": "DIARRHOEA", "count": 19 },
      { "term": "RASH", "count": 14 },
      { "term": "FATIGUE", "count": 11 }
    ],
    "signals": []
  },
  "literatureMomentum": {
    "score": 52,
    "publicationCount": 47,
    "recentPublications": 18,
    "yearlyTrend": {
      "2022": 8,
      "2023": 11,
      "2024": 15,
      "2025": 13
    },
    "accelerating": true,
    "topJournals": [
      "Journal of Cystic Fibrosis",
      "American Journal of Respiratory and Critical Care Medicine",
      "Thorax",
      "Pediatric Pulmonology",
      "ERJ Open Research"
    ],
    "signals": [
      "18 publications in last 2 years",
      "Publication rate accelerating (28 recent vs 19 prior 2yr)"
    ]
  },
  "allSignals": [
    "2 recent FDA approvals in class",
    "5.4 years patent exclusivity remaining",
    "Already has 2 FDA approval(s)",
    "18 publications in last 2 years",
    "Publication rate accelerating (28 recent vs 19 prior 2yr)"
  ]
}

⬆️ Output fields

| Field | Type | Description |
|-------|------|-------------|
| company | string | Company name as provided in the request |
| drug | string | Drug name as provided in the request |
| compositeScore | number | Overall Pipeline Threat Score, 0-100 |
| riskLevel | string | LOW / MODERATE / HIGH / CRITICAL |
| pipelineThreat.score | number | Competitive threat sub-score, 0-100 |
| pipelineThreat.competitorCount | number | Total competitors across trials, FDA, and EMA |
| pipelineThreat.phaseDistribution | object | Trial counts keyed by phase label |
| pipelineThreat.sameIndicationTrials | number | Active trials in the same indication |
| pipelineThreat.recentApprovals | number | Recent FDA approvals in the drug class |
| pipelineThreat.recentRecalls | number | Recent competitor drug recalls |
| pipelineThreat.threatLevel | string | LOW / MODERATE / HIGH / CRITICAL |
| pipelineThreat.signals | string[] | Human-readable trigger explanations |
| firstMoverAdvantage.score | number | First-mover advantage sub-score, 0-100 |
| firstMoverAdvantage.patentsCovering | number | USPTO patents found for the drug |
| firstMoverAdvantage.earliestPatentExpiry | string | Date string of the nearest patent expiry |
| firstMoverAdvantage.yearsOfExclusivity | number | Years of patent protection remaining |
| firstMoverAdvantage.trialPhaseLead | number | Highest clinical phase found in data (1-4) |
| firstMoverAdvantage.approvalPathwayClear | boolean | True if approved or in Phase 3+ |
| firstMoverAdvantage.signals | string[] | Patent and approval signal explanations |
| adverseEventDivergence.score | number | Adverse event divergence sub-score, 0-100 |
| adverseEventDivergence.totalReports | number | Total FAERS reports analyzed |
| adverseEventDivergence.seriousEvents | number | Reports classified as serious |
| adverseEventDivergence.deathReports | number | Reports with fatal outcomes |
| adverseEventDivergence.hospitalizationReports | number | Reports with hospitalization |
| adverseEventDivergence.seriousRatio | number | Fraction of reports that are serious |
| adverseEventDivergence.divergenceLevel | string | NORMAL / ELEVATED / CONCERNING / CRITICAL |
| adverseEventDivergence.topReactions | array | Top 10 MedDRA reaction terms with counts |
| adverseEventDivergence.signals | string[] | Adverse event signal explanations |
| literatureMomentum.score | number | Literature momentum sub-score, 0-100 |
| literatureMomentum.publicationCount | number | Total PubMed publications found |
| literatureMomentum.recentPublications | number | Publications in the last 2 years |
| literatureMomentum.yearlyTrend | object | Publication counts keyed by year |
| literatureMomentum.accelerating | boolean | True if recent 2yr count exceeds prior 2yr by 20%+ |
| literatureMomentum.topJournals | string[] | Top 5 journals by publication count |
| literatureMomentum.signals | string[] | Momentum signal explanations |
| allSignals | string[] | Merged signals from all four sub-models |

How much does it cost to run drug pipeline analysis?

Pharma Pipeline Intelligence MCP uses pay-per-event pricing — each tool call costs $0.045. There is no subscription, no minimum commitment, and no charge for idle time between calls.

| Scenario | Tool calls | Cost per call | Total cost |
|----------|------------|---------------|------------|
| Quick test — single trial search | 1 | $0.045 | $0.045 |
| Spot check — 5 individual tools | 5 | $0.045 | $0.23 |
| Weekly landscape update — 20 calls | 20 | $0.045 | $0.90 |
| Monthly monitoring — 3 therapeutic areas | 60 | $0.045 | $2.70 |
| Daily competitive surveillance | 200 | $0.045 | $9.00 |

You can set a maximum spending limit per session in Apify Console. The server stops charging and returns a structured error once your budget is reached — no surprise overruns when an AI assistant runs exploratory queries.

Comparable dedicated pharma intelligence platforms (Citeline Pharma R&D, Clarivate Cortellis, GlobalData) charge $15,000–$50,000 per year for similar regulatory and pipeline data access. Most users of this MCP spend $2–$10 per month with no subscription commitment.

How to connect this MCP server

Claude Desktop

Add to your claude_desktop_config.json:

{
  "mcpServers": {
    "pharma-pipeline": {
      "url": "https://pharma-pipeline-intelligence-mcp.apify.actor/mcp",
      "headers": {
        "Authorization": "Bearer YOUR_APIFY_TOKEN"
      }
    }
  }
}

Cursor

In Cursor Settings → MCP → Add Server:

{
  "pharma-pipeline": {
    "url": "https://pharma-pipeline-intelligence-mcp.apify.actor/mcp",
    "headers": {
      "Authorization": "Bearer YOUR_APIFY_TOKEN"
    }
  }
}

Programmatic HTTP (cURL)

```bash